Abstract
The National Lung Matrix Trial, an umbrella trial of targeted therapies in non-small cell lung cancer, revealed that most drugs prescribed based on specific genomic aberrations showed little efficacy, but new approaches could bolster precision medicine.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
